SG10202007210RA - Compositions and methods for treatment of microbial disorders - Google Patents
Compositions and methods for treatment of microbial disordersInfo
- Publication number
- SG10202007210RA SG10202007210RA SG10202007210RA SG10202007210RA SG10202007210RA SG 10202007210R A SG10202007210R A SG 10202007210RA SG 10202007210R A SG10202007210R A SG 10202007210RA SG 10202007210R A SG10202007210R A SG 10202007210RA SG 10202007210R A SG10202007210R A SG 10202007210RA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- treatment
- methods
- microbial disorders
- microbial
- Prior art date
Links
- 230000000813 microbial effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98617007P | 2007-11-07 | 2007-11-07 | |
US1362007P | 2007-12-13 | 2007-12-13 | |
US1562007P | 2007-12-20 | 2007-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202007210RA true SG10202007210RA (en) | 2020-08-28 |
Family
ID=40551983
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202007210RA SG10202007210RA (en) | 2007-11-07 | 2008-11-07 | Compositions and methods for treatment of microbial disorders |
SG2012082434A SG185972A1 (en) | 2007-11-07 | 2008-11-07 | Compositions and methods for treatment of microbial disorders |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012082434A SG185972A1 (en) | 2007-11-07 | 2008-11-07 | Compositions and methods for treatment of microbial disorders |
Country Status (26)
Country | Link |
---|---|
US (4) | US20090202475A1 (ru) |
EP (3) | EP2217263A2 (ru) |
JP (3) | JP5985150B2 (ru) |
KR (2) | KR101867606B1 (ru) |
CN (5) | CN104888193A (ru) |
AU (1) | AU2008323770B2 (ru) |
CA (1) | CA2705007A1 (ru) |
CO (1) | CO6280406A2 (ru) |
DK (1) | DK2514436T3 (ru) |
ES (1) | ES2662845T3 (ru) |
HK (2) | HK1214137A1 (ru) |
HR (1) | HRP20180445T1 (ru) |
HU (1) | HUE038588T2 (ru) |
IL (2) | IL205623A0 (ru) |
LT (1) | LT2514436T (ru) |
MX (1) | MX2010005108A (ru) |
NO (1) | NO2514436T3 (ru) |
PH (1) | PH12013501074A1 (ru) |
PL (1) | PL2514436T3 (ru) |
PT (1) | PT2514436T (ru) |
RS (1) | RS57021B1 (ru) |
RU (1) | RU2503460C2 (ru) |
SG (2) | SG10202007210RA (ru) |
SI (1) | SI2514436T1 (ru) |
WO (1) | WO2009062102A2 (ru) |
ZA (1) | ZA201003113B (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗脂肪肝中的应用 |
CA2741566A1 (en) * | 2008-11-03 | 2010-06-03 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
WO2011046616A2 (en) * | 2009-10-15 | 2011-04-21 | New York University | Methods for modulating bacterial infection |
US20130130965A1 (en) * | 2010-04-08 | 2013-05-23 | University Of Virginia Patent Foundation | Method to detect and treat infectious or inflammatory diarrhea based on reg1 |
CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术(上海)有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
CN102380091A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
AU2012289433B2 (en) | 2011-07-25 | 2017-07-27 | Evive Biotechnology (Shanghai) Ltd | Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases |
US11119097B2 (en) | 2011-12-05 | 2021-09-14 | The Trustees Of The University Of Pennsylvania | Graphene-biomolecule bioelectronic devices |
CN102559759A (zh) * | 2011-12-19 | 2012-07-11 | 西安交通大学医学院第一附属医院 | Hip/pap重组腺病毒及其抗溃疡性结肠炎的应用 |
CN103182072B (zh) | 2011-12-27 | 2017-05-03 | 健能隆医药技术(上海)有限公司 | 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途 |
KR101431324B1 (ko) * | 2012-08-20 | 2014-08-20 | 성균관대학교산학협력단 | WKYMVm 펩티드를 포함하는 염증성 장질환 예방 또는 치료용 약학적 조성물 |
US9314504B2 (en) * | 2013-03-14 | 2016-04-19 | Taipei Medical University | Use of members of IL-10 cytokine family |
WO2014139182A1 (en) | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
WO2014145016A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
US10646548B2 (en) * | 2013-10-08 | 2020-05-12 | Georgia State University Research Foundation, Inc. | Compositions including IL-18 and IL-22 and their use in anti-viral therapies |
CN103554267A (zh) * | 2013-10-15 | 2014-02-05 | 山西农业大学 | 一种具有抗菌功能的融合蛋白及其构建方法和应用 |
JP5515104B1 (ja) * | 2013-10-25 | 2014-06-11 | 独立行政法人農業・食品産業技術総合研究機構 | 抗酸菌の増殖促進剤、これを添加して培養する抗酸菌の培養方法、及び、これを含有する抗酸菌の培養用培地 |
CN112386680A (zh) * | 2013-11-07 | 2021-02-23 | 纪念斯隆–凯特林癌病中心 | 在胃肠道移植物抗宿主病的治疗中使用il-22的方法 |
CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
CN109180786B (zh) * | 2015-11-20 | 2021-06-18 | 深圳市南山区人民医院 | 用于预防和治疗肠致病大肠杆菌感染的肽段 |
WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
MA45035A (fr) * | 2016-05-18 | 2019-03-27 | Modernatx Inc | Combinaisons d'arnm codant pour des polypeptides de modulation immunitaire et leurs utilisations |
US11484569B2 (en) * | 2017-07-13 | 2022-11-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Polypeptide for use in the protection of oxygen sensitive gram-positive bacteria |
US20240150453A1 (en) | 2021-03-09 | 2024-05-09 | Massachusetts Institute Of Technology | Methods of predicting response to anti-tnf blockade in inflammatory bowel disease |
CN113304247B (zh) * | 2021-04-01 | 2024-03-19 | 上海市儿科医学研究所 | Reg4蛋白及其在抵抗肠炎伤寒沙门氏菌感染中的应用 |
CN114409758A (zh) * | 2022-01-24 | 2022-04-29 | 上海市儿科医学研究所 | Reg4抗菌肽治疗致病性大肠埃希菌感染的应用 |
CN114344451B (zh) * | 2022-01-25 | 2023-09-26 | 上海市肺科医院 | Reg4抗菌肽治疗铜绿假单胞菌感染性肺炎的应用 |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US5683688A (en) | 1984-05-31 | 1997-11-04 | Genentech, Inc. | Unglycosylated recombinant human lymphotoxin polypeptides and compositions |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
CA2071483C (en) | 1989-10-24 | 2001-04-17 | Mark Matteucci | Oligonucleotide analogs with novel linkages |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DK0536299T3 (da) | 1990-06-27 | 2001-07-09 | Univ California | Overfladekompleksbundet lymfotolksin |
ES2162789T3 (es) | 1990-06-29 | 2002-01-16 | Large Scale Biology Corp | Produccion de melanina por microorganismos transformados. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
ATE176239T1 (de) | 1990-11-21 | 1999-02-15 | Iterex Pharma Lp | Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用 |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methoden zur Herstellung humanisierter Antikörper |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
PL174494B1 (pl) | 1992-11-13 | 1998-08-31 | Idec Pharma Corp | Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
WO1997038123A1 (en) | 1996-04-05 | 1997-10-16 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
US20030003545A1 (en) * | 1998-05-29 | 2003-01-02 | Reinhard Ebner | Interleukins-21 and 22 |
US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
WO2000039585A1 (en) | 1998-12-28 | 2000-07-06 | Sunesis Pharmaceuticals, Inc. | Identifying small organic molecule ligands for binding |
EP2386574A3 (en) | 1999-01-15 | 2012-06-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP3031917A1 (en) | 1999-04-09 | 2016-06-15 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6939545B2 (en) * | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
US20030170823A1 (en) * | 1999-12-23 | 2003-09-11 | Presnell Scott R. | Novel cytokine ZCYTO18 |
GB0024442D0 (en) * | 2000-10-05 | 2000-11-22 | Isis Innovation | Genetic factors affecting the outcome of viral infections |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
FR2833011B1 (fr) * | 2001-12-04 | 2004-10-29 | Univ Claude Bernard Lyon | Nouvelle proteine a activite inhibitrice de l'il-6 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
WO2003085102A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
WO2003089575A2 (en) | 2002-04-15 | 2003-10-30 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tl5 |
EP1539235A2 (en) * | 2002-07-01 | 2005-06-15 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
ES2633311T3 (es) | 2002-12-16 | 2017-09-20 | Genentech, Inc. | Variantes de inmunoglobulina y usos de las mismas |
US20040176293A1 (en) * | 2002-12-18 | 2004-09-09 | Wyeth | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
EP1644415B1 (en) * | 2003-06-23 | 2010-12-01 | Genetics Institute, LLC | Antibodies against interleukin-22 and uses therefor |
EP1660632B1 (en) * | 2003-08-01 | 2014-02-19 | Stratatech Corporation | Human skin equivalents expressing exogenous polypeptides |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
ME03330B (me) | 2003-11-05 | 2019-10-20 | Roche Glycart Ag | Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
US20050277593A1 (en) * | 2004-05-24 | 2005-12-15 | Washington University | Therapeutic uses of Reg protein |
RU2302460C1 (ru) * | 2005-11-02 | 2007-07-10 | Институт цитологии и генетики Сибирского отделения Российской академии наук (СО РАН) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBi101-IL18, КОДИРУЮЩАЯ СИНТЕЗ ИНТЕРЛЕЙКИНА-18 ЧЕЛОВЕКА В ТРАНСГЕННЫХ РАСТЕНИЯХ |
MX2008015446A (es) * | 2006-06-19 | 2008-12-12 | Wyeth Corp | Metodos de modulacion il-22 e il-17. |
-
2008
- 2008-11-07 HU HUE12169572A patent/HUE038588T2/hu unknown
- 2008-11-07 RU RU2010122982/10A patent/RU2503460C2/ru active
- 2008-11-07 AU AU2008323770A patent/AU2008323770B2/en not_active Ceased
- 2008-11-07 EP EP08848478A patent/EP2217263A2/en not_active Withdrawn
- 2008-11-07 EP EP12169572.0A patent/EP2514436B1/en active Active
- 2008-11-07 SG SG10202007210RA patent/SG10202007210RA/en unknown
- 2008-11-07 WO PCT/US2008/082890 patent/WO2009062102A2/en active Application Filing
- 2008-11-07 JP JP2010533299A patent/JP5985150B2/ja active Active
- 2008-11-07 KR KR1020107012426A patent/KR101867606B1/ko active IP Right Grant
- 2008-11-07 NO NO12169572A patent/NO2514436T3/no unknown
- 2008-11-07 ES ES12169572.0T patent/ES2662845T3/es active Active
- 2008-11-07 LT LTEP12169572.0T patent/LT2514436T/lt unknown
- 2008-11-07 MX MX2010005108A patent/MX2010005108A/es active IP Right Grant
- 2008-11-07 CN CN201510262894.6A patent/CN104888193A/zh active Pending
- 2008-11-07 CA CA2705007A patent/CA2705007A1/en not_active Abandoned
- 2008-11-07 DK DK12169572.0T patent/DK2514436T3/en active
- 2008-11-07 SI SI200831926T patent/SI2514436T1/en unknown
- 2008-11-07 CN CN2013100500120A patent/CN103142999A/zh active Pending
- 2008-11-07 CN CN2011101151819A patent/CN102172395A/zh active Pending
- 2008-11-07 CN CN2008801241737A patent/CN101951945A/zh active Pending
- 2008-11-07 US US12/291,380 patent/US20090202475A1/en not_active Abandoned
- 2008-11-07 EP EP17208162.2A patent/EP3360567A1/en not_active Withdrawn
- 2008-11-07 SG SG2012082434A patent/SG185972A1/en unknown
- 2008-11-07 PT PT121695720T patent/PT2514436T/pt unknown
- 2008-11-07 CN CN201811093788.XA patent/CN108815508A/zh active Pending
- 2008-11-07 RS RS20180324A patent/RS57021B1/sr unknown
- 2008-11-07 PL PL12169572T patent/PL2514436T3/pl unknown
- 2008-11-07 KR KR1020167030030A patent/KR20160129099A/ko not_active Application Discontinuation
-
2010
- 2010-05-04 ZA ZA2010/03113A patent/ZA201003113B/en unknown
- 2010-05-09 IL IL205623A patent/IL205623A0/en unknown
- 2010-05-26 CO CO10063303A patent/CO6280406A2/es not_active Application Discontinuation
-
2011
- 2011-05-20 US US13/112,850 patent/US20110280828A1/en not_active Abandoned
-
2012
- 2012-08-03 US US13/566,760 patent/US20130052159A1/en not_active Abandoned
-
2013
- 2013-05-27 PH PH12013501074A patent/PH12013501074A1/en unknown
-
2014
- 2014-09-30 JP JP2014200490A patent/JP6266486B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-24 HK HK16102060.3A patent/HK1214137A1/zh unknown
- 2016-03-09 JP JP2016045739A patent/JP2016117760A/ja active Pending
-
2018
- 2018-03-15 HR HRP20180445TT patent/HRP20180445T1/hr unknown
- 2018-04-16 IL IL258730A patent/IL258730A/en unknown
-
2019
- 2019-01-29 HK HK19101602.7A patent/HK1259102A1/zh unknown
-
2021
- 2021-01-29 US US17/162,924 patent/US20210338778A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL258730A (en) | Preparations and methods for the treatment of microbial disorders | |
EP2120580A4 (en) | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | |
EP2293800A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EARLIER DISEASES | |
EP2170309A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
IL209032A0 (en) | Compositions and methods for treating digestive disorders | |
IL202573A0 (en) | Methods and compositions for treating allergic diseases | |
EP2211881A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AFFECTING MAMMALS | |
PL2182981T3 (pl) | Sposoby i kompozycje do leczenia i diagnozowania zwłóknienia | |
GB201001047D0 (en) | Methods and compositions for the treatment of neurological disorders | |
EP2361089A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE | |
ZA201001810B (en) | Seed treatment compositions and methods | |
ZA201001811B (en) | Seed treatment compositions and methods | |
EP2134363A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CERVICAL CANCER OF THE UTERUS | |
IL193936A0 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
EP2016187A4 (en) | COMPOSITIONS AND METHODS FOR ENZYMATIC TREATMENT OF PULMONARY DISEASES | |
HK1160598A1 (zh) | 治療腎功能紊亂的組合物和方法 | |
PT2300614E (pt) | Métodos e composições para tratamento de distúrbios mitocondriais | |
HK1245679A1 (zh) | 用於治療皮膚疾病和病症的方法和組合物 | |
GB0718446D0 (en) | Compositions and methods for the treatment of infection | |
IL198723A0 (en) | Methods and compositions for therapeutic treatment | |
EP2217238A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA | |
EP2021005A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN | |
EP2285398A4 (en) | METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS | |
EP2219650A4 (en) | COMPOSITIONS AND METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS | |
EP2142566A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |